BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate-548 Study for Patients Newly Diagnosed with MGMT-Methylated Glioblastoma Multiforme

BMS Reports Results of Opdivo (nivolumab) in P-III CheckMate-548 Study for Patients Newly Diagnosed with MGMT-Methylated Glioblastoma Multiforme

Shots:

  • The P-III CheckMate-548 (NCT02667587) study involves assesing of Opdivo + SoC (temozolomide & radiation therapy) vs SoC monothx in patients newly diagnosed GBM that is MGMT-methylated, with its 1EP as PFS per blinded independent central review (BICR) & OS and 2EPs as investigator assess PFS & OS rate ~2yrs.
  • The study resulted in unmet one of its 1EP showing no improvement in PFS for patients
  • Opdivo is a PD-1 immune checkpoint inhibitor targeted to harness body’s own immune system further restoring anti-immune response and is approved in 65+ countries including the US, EU, Japan and China

Click here to read full press release/ article | Ref: Bristol-Myers Squibb | Image: The Street